Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 2 of 37                                                       Version 1.0 08 AUG 2016   
Protocol Signa ture Page  – Principal Investigator  
 
 
PROTOCOL C -16-EN14  
 
 
Study Title:   A Single -Center Pilot Study of a Novel  Multi -Wavelength Laser for Tattoo Removal  
 
 
Protocol Version 1.0, Dated August  08, 2016  
 
I have received and read the protocol dated August  08, 2016 and agree to adhere to the requirements. I 
am aware that my adherence to the above protocol is mandatory and that any changes in the protocol or 
informed consent form must first be approved by Cutera, Inc. and the Independent Review Board 
(IRB)/Ethics Comm ittee (EC) , except those changes necessary to eliminate apparent immediate hazards 
to subjects.  I will provide copies of this protocol and all pertinent information to the study personnel 
under my supervision. I will discuss this material with them and en sure they are fully informed regarding 
their role in the study. I will ensure that the study is conducted in compliance with the protocol, Good 
Clinical Practice (GCP), and all applicable regulatory requirements, and with the reviewing IRB/EC 
requirements.  I agree to commence this study only after documented IRB/ EC approval is obtained.  
 
 
 
 
Principal 
Investigator      
  Signature   Date  
 
 
     
  Printed Name    
 
 
 
 
 
  
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 3 of 37                                                       Version 1.0 08 AUG 2016  Table of Contents  
Protocol Summary  ................................ ................................ ................................ ................................ .......... 6 
1 PURPOSE  ................................ ................................ ................................ ................................ ................ 7 
2 BACKGROUND INFORMATION  ................................ ................................ ................................ ............... 7 
2.1 Tattoo Removal  ................................ ................................ ................................ ................................ ...7 
3 STUDY OBJECTIVES  ................................ ................................ ................................ ................................ .9 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ........ 9 
4.1 Study Endpoints  ................................ ................................ ................................ ................................ 10 
4.1.1  Efficacy endpoints  ................................ ................................ ................................ ......................... 10 
4.1.1.1  Primary Efficacy Endpoint  ................................ ................................ ................................ .......... 10 
4.1.1.2  Secondary Efficacy Endpoints  ................................ ................................ ................................ ....10 
4.1.2  Exploratory Efficacy Endpoint  ................................ ................................ ................................ ....... 10 
4.1.3  Safety Endpoint  ................................ ................................ ................................ ............................. 10 
4.2 Study Duration  ................................ ................................ ................................ ................................ ..10 
4.3 Blinding and Randomization of Photographs  ................................ ................................ ................... 11 
4.3.1  Blinding  ................................ ................................ ................................ ................................ .......... 11 
4.3.2  Randomization of Photographs  ................................ ................................ ................................ .....11 
4.4 Study Effectiveness Assessments  ................................ ................................ ................................ ......11 
4.4.1  Investigator Assessments  ................................ ................................ ................................ .............. 11 
4.4.2  Subject Assessments  ................................ ................................ ................................ ..................... 11 
4.4.3  Exploratory Blinded Assessment  ................................ ................................ ................................ ...12 
4.5 Study Safety Assessments ................................ ................................ ................................ .......... 12 
4.6 Photographs  ................................ ................................ ................................ ................................ ..13 
4.7 Study Discontinuation  ................................ ................................ ................................ ................... 13 
4.8 Investigator Selection  ................................ ................................ ................................ .................... 13 
5 STUDY POPULATION  ................................ ................................ ................................ ............................. 13 
5.1 Study Subject Recruitment and Selection  ................................ ................................ ..................... 13 
5.1.1  Inclusion Criteria  ................................ ................................ ................................ .................... 13 
5.1.2  Exclusion Criteria  ................................ ................................ ................................ .................... 14 
5.2 Subject Numbering  ................................ ................................ ................................ ........................ 15 
5.3 Subject Discontinuation Criteria ................................ ................................ ................................ ....15 
6 STUDY PROCEDURES  ................................ ................................ ................................ ............................ 15 
6.1 Screening / Enrollment Procedures  ................................ ................................ ................................ ..15 
6.2 Laser Treatment Visits – Pre-Treatment Procedures  ................................ ................................ ........ 16 
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 4 of 37                                                       Version 1.0 08 AUG 2016  6.3 Laser Treatment Procedures – All Visits  ................................ ................................ ........................... 16 
6.4 Follow -Up Visits  ................................ ................................ ................................ ................................ .17 
6.5 Biopsy Procedure  ................................ ................................ ................................ ........................... 17 
6.6 Biopsy Suture Removal Visit (as applicable)  ................................ ................................ .................. 18 
7 ADVERSE DEVICE EFFECTS  ................................ ................................ ................................ .................... 18 
7.1 Definitions  ................................ ................................ ................................ ................................ ......... 18 
7.1.1  Adverse Device Effect  ................................ ................................ ................................ .................... 18 
7.1.2  Serious Adverse Device Effect  ................................ ................................ ................................ ....... 18 
7.1.2.1  Anticipated Serious A dverse Device Effect (ASADE)  ................................ ................................ ...19 
7.1.2.2  Unanticipated Serious Adverse Device Effect (USADE/UADE)  ................................ ................... 19 
7.2 Recording ADEs and SADEs  ................................ ................................ ................................ ............... 21 
7.3 Follow -up of Subjects after ADEs and SADEs:  ................................ ................................ ................... 21 
8 POTENTIAL RISKS / BENEFITS  ................................ ................................ ................................ ............... 21 
8.1 Potential Risks  ................................ ................................ ................................ ................................ ...21 
8.2 Potential Benefits  ................................ ................................ ................................ .............................. 23 
9 RISK MANAGEMENT  ................................ ................................ ................................ ............................. 23 
10 DATA ANALYSIS PLAN  ................................ ................................ ................................ ............................ 23 
10.1  Sample Size  ................................ ................................ ................................ ................................ ........ 23 
10.2  Demographics and Subject Characteristics at Baseline  ................................ ................................ ....23 
10.3  Statistical Analysis Methods  ................................ ................................ ................................ .............. 23 
10.3.1  Analysis Sets  ................................ ................................ ................................ ................................ ..23 
10.3.2  Analysis of Primary Endpoint ................................ ................................ ................................ ......... 23 
10.3.3  Analyses of Secondary Endpoints  ................................ ................................ ................................ ..23 
10.3.4  Safety Analyses  ................................ ................................ ................................ .............................. 24 
11 SUBJECT PAYMENT  ................................ ................................ ................................ ............................... 24 
12 STUDY MANAGEMENT AND ADMINISTRATIVE PROCEDURES  ................................ ............................. 24 
12.1  Training and Monitoring  ................................ ................................ ................................ .................... 24 
12.2  Informed Consent  ................................ ................................ ................................ ............................. 24 
12.3  Protocol Compliance  ................................ ................................ ................................ ......................... 25 
12.3.1  Protocol Amendments  ................................ ................................ ................................ ................... 25 
12.3.2  Protocol Deviations  ................................ ................................ ................................ ........................ 25 
12.4  Study Personnel ................................ ................................ ................................ ................................ .25 
12.5  Disclosure of Financial Interest  ................................ ................................ ................................ ......... 26 
12.6  Data Collection, Record Keeping and Storage  ................................ ................................ ................... 26 
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 5 of 37                                                       Version 1.0 08 AUG 2016  13 SUBJECT CONFIDENTIALITY  ................................ ................................ ................................ .................. 27 
14 PUBLICATION POLICY ................................ ................................ ................................ ............................ 28 
REFERENCES  ................................ ................................ ................................ ................................ ................. 29 
Appendix 1: Study Schedule  ................................ ................................ ................................ ......................... 31 
Appendix 2: Pain Rating Scale  ................................ ................................ ................................ ...................... 32 
Appendix 3: Fitzpatrick Skin Type Classification  ................................ ................................ .......................... 33 
Appendix 4:  Before and After Treatment Instructions  ................................ ................................ ............... 34 
Appendix 5:  Follow -Up Subject Questionnaire  ................................ ................................ ........................... 35 
Appendix 6: Before and After Biopsy Instructions  ................................ ................................ ....................... 37 
 
  
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 6 of 37                                                       Version 1.0 08 AUG 2016  Protocol Summary  
 
Title  A Single -Center Pilot Study  of a Novel Multi -Wavelength Laser for Tattoo 
Removal  
Objective  
 To evaluate the safety and efficacy of an investigational version of the 
Cutera enlightenTM laser that offers multiple wavelengths for tattoo 
removal.  
Study Design  A single -center prospective, open -label , uncontrolled  pilot study.  
Enrollment  A maximum of 10 subjects  
Primary Endpoint  • Degree of tattoo clearing  at 6 weeks post -final treatment as 
assessed by the Investigator (Physician’s Global Assessment 
of Improvement).  
 
 
 
 
  
  
 
 
  
  
 
 
 
Subject Population  Female or male subjects, age 18 to 6 5 years, Fitzpatrick skin types I -VI 
Planned Schedule  First subject enrolled:  Septem ber 2016 
Last subject last visit:  December 2018 
  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 8 of 37                                                       Version 1.0 08 AUG 2016  because of decreased melanin absorption. Still, lower fluences are recommend ed for treatment of 
darker skin patients with Nd:YAG lasers.  Scarring is rarely observed following treatments with QS lasers 
as water is no longer the target chromophore.  
 
There are some challenges associated with tattoo removal. If mixtures of pigments a nd/or multicolors 
are used, a complete clearing of the tattoo may not be achieved with lasers [19].  Different colors are 
usually mixed to achieve various levels of brightness and lightness. Another contributing factor to 
unsuccessful outcome is that most tattoo pigments are not regulated and may include various elements 
and chemical compounds.  When the exact compound of the tattoo pigment is not known, paradoxical 
darkening of the pigment ma y happen following tattoo removal, which may be difficult to remove [20-
23].  Additionally, white, orange, yellow and brown tattoo inks are particularly difficult to treat [24]. 
 
Although the mechanism of action is not clea rly understood, the effects of the lasers on the pigment are 
thought to be: 1) photothermal/photochemical and 2) photoacoustic/photomechanical [25, 26].  
Conver sion of absorbed energy into heat (photothermal effect) breaks the chemical bonds inside the 
pigment and causes pigment modification.  At the same time, the ultrashort heating of the particle shell 
may cause heating of the surrounding tissue via rapid ther mal expansion resulting in shock waves. These 
shock waves may help destroy the surrounding cellular structures and tattooed compounds 
mechanically (photoacoustic/photomechanical). The resultant fragmented particles are then removed 
by three mechanisms: 1) transepidermal elimination, 2) removal via lymphatics, and 3) rephagocytosis 
by other cells (inflammatory or resident cells) in the dermis.  
 
Histological examinations show that the tattoo pigments are exclusively found intracytoplasmatically in 
lysosomes w hich is a result of active phagocytosis in dermal cells, such as macrophages and 
fibroblasts [27, 28]. In electron microscopy of black tattoos immediately after treatment with 1064 nm 
Nd:YAG, vacuoles were observed in th e dermis [29].  Vacuoles were lined by remnants of pigment -
containing cells, flattened cell nuclei and disrupted lysosomes. Cells without pigment located close to 
the vacuoles were not affected. One week after treatment, a moderate chronic in flammatory infiltrate 
was observed in the dermis and all tattoo particles were phagocytosed and intracellular within 
fibroblasts and macrophages. At one month post -treatment, all residual pigment particles were within 
lysosomes with mild residual inflammat ory infiltrate around dermal vessels.  
 
Although nanosecond QS lasers are safe and effective in the treatment of tattoos, treatment sessions 
are often painful and as many as 6 to 10 treatments are necessary to achieve acceptable clearance. It 
could be argue d that this is a result of most tattoo particles ranging in size from 40 to 300 nm in vivo and 
their thermal relaxation times being mostly in the picosecond range [30].  For example, the most 
common pigment particle, carbon black in india ink, which is shown to be about 40 nm in diameter, will 
approximately have a thermal relaxation time of 1 nanosecond [31]. In that case, a thermally confined 
disruption of the particle can only be achieved via picosecond pulses.  This suggests that energy delivery 
in the picosecond range be more effective and require lower fluences than the nanosecond range.  
Moreover, the resultant ultra -short pulses with higher peak temper atures should decrease adverse 
effects, such as dyspigmentation as the heat transfer to the surrounding tissue is significantly minimized.   
 
Up to date, various studies of picosecond QS lasers, both in vitro and in vivo, have been conducted to 
test the hypotheses on the potential benefits of picosecond QS lasers [30-34].  In a split -tattoo study, 
Ross et all reported better clearing in 75% (12/16)  of tattoos with on picosecond side than the clearing 
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 10 of 37                                                       Version 1.0 08 AUG 2016   
 
 
  
 
 
 
 
 
   
4.1 Study Endpoints  
4.1.1 Efficacy endpoints  
4.1.1.1  Primary Efficacy Endpoint  
• Degree of tattoo clearing  at 6 weeks post -final treatment as assessed by the Investigator 
(Physician’s Global Assessment of Improvement).  
  
  
 
  
  
  
 
4.1.3 Safety Endpoint  
• Incidence and severity of adverse device effects during the study period, including subject pain 
level during laser  treatment.  
 
4.2 Study Duration  
Subjects enrolled in this trial will be asked to participate for up to 15 months ,  
.   1 screening visit,  
 laser treatment visits , and  1 required  follow -up visit  at 6 weeks  
) post -final tre atment. At the Investigat or’s discretion, an optional follow -up visit may be 
conducted at 12 weeks  post -final treatment . 
 
The screening and first laser  treatment may be combined into one visit  provided that the informed 
consent process has been completed (see Section 1 2.2) and the subject has signed the  IRB/EC-approved 
Informed Consent Form prior to  the commencement of any study -related pr ocedures and device 
treatments.  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 11 of 37                                                       Version 1.0 08 AUG 2016  4.3 Blinding and Randomizati on of Photographs  
4.3.1 Blinding  
A panel of independent reviewers may assess subject photographs taken at baseline , 6 weeks and 12 
weeks post -final treatment. The reviewers will be blinded to the type of treatment device, the 
parameters used, the subject data, the temporal order of photographs (before and after), and follow -up 
time point.  
4.3.2 Randomization of Photographs  
The presentation order of subject photographs will be randomized. First, a unique identification number 
will be assigned to each pair of subj ect photographs (1 baseline and 1 post -treatment), then the order of 
photograph presentation will be assigned by randomizing the identification numbers. In addition, the 
location of the baseline photograph on the assessment page will be randomized such tha t each 
photograph pair will be arranged with the baseline photograph located either on the right side or left 
side of the page. Minitab statistical package, version 16.2.2.0 (Minitab Inc., State College, Pennsylvania) 
will be used to do randomizations. The  photograph pairs from each subject will be then organized 
according to randomization and will be presented to the blinded reviewers for assessment.  
 
4.4 Study Effectiveness Assessments  
4.4.1 Investigator Assessments  
4.4.1.1  Investigator’s Global Assessment of Improvement  
At 6 weeks , , the Investigator will be asked to rate the 
degree of tattoo clearing  observed in the subject’s treated area  using the Physician’s Global Assessment 
of Improvement Scale:   
 
4 = Very Significant or Complete Clearing (  
3 = Significant Clearing  
2 = Moderate Clearing  
1 = Mild Clearing (  
0 = No Clearing  
 
  
  
 
 
 
 
 
 
 
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 12 of 37                                                       Version 1.0 08 AUG 2016  0  
 
  
 
 
  
 
  
  
  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
4.5 Study Safety Assessments  
4.5.1 Incidence and Severity of Adverse Events:   
Following the first laser treatment, adverse device effects (ADEs) will be assessed post -treatment and at 
each subsequent subject visit using the following scale:  
 
1= mild: requires minimal or no treatment and does not interfere with the Subject’s daily activities.  
2= moderate: may cause some interference with functioning.  
3= severe: interrupts Subject’s usual daily activity and may require treatme nt. 
4.5.2 Treatment -related Discomfort  
Subjects will be asked to rate the average amount of discomfort experienced during laser treatment 
using the Pain Rating Scale found in Appendix 2.  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 13 of 37                                                       Version 1.0 08 AUG 2016  4.6 Photographs  
Standardized digital photographs will be taken of each subject’ s treatment area at baseline, prior to all 
laser treatments , immediately following laser treatments and at each follow -up visit. Any jewelry will be 
removed from the area being photographed.  Photographs will be taken in the same windowless room 
equipped with adequate lighting. The room lighting, camera positioning and subject positioning should 
be consistent for all study visit photographs. Digital camera settings (including any flash settings ) should 
remain the same for all photographs and the highest resolution settings should be utilized.  
4.7 Study Discontinuation  
The sponsor  (Cutera, Inc. ) has the right to terminate this study at any time.  Reasons for terminating the 
study  may include, but are  not limited to , the following: incidence or severity of adverse events in this or 
other studies indicates a potential health hazard to subjects; subject enrollment is unsatisfactory; 
number of protocol deviations is unacceptable; data recording is inaccur ate or incomplete; or 
questionable study site compliance with ICH -E6, Good Clinical Practice.  
4.8 Investigator Selection  
The Investigator will be invited to participate in the study based on his or her medical specialty, 
experience conducting clinical research studies and experience in the use of light -based devices for 
aesthetic indications. Access to potential study subjec ts and the Investigator’s sincere interest in this 
study along with expressed willingness to cooperate with the study process and requirements was also 
considered.  
5 STUDY POPULATION  
5.1 Study Subject Recruitment and Selection  
Up to 10 male or female subjects, ages 18 to 6 5, with Fitzpatrick Skin Type I -VI who desire laser  
treatment for tattoo removal will be studied. Subjects will be recruited to participate from the local 
population. Subjects may also be recruited from the Investigator’s existing patient database or from 
patients who present themselves to the stu dy site requesting treatment. Only subjects who meet study 
eligibility criteria and who provide written informed consent will be enrolled into the study.  
 
Each subject will be evaluated by the Investigator to assess his/her suitability for entry into the study 
according to the following inclusion and exclusion criteria.  
5.1.1 Inclusion Criteria  
To be included in the study, subjects must meet all of the following Inclusion Criteria:  
1.  Female or Mal e, 18 to 6 5 years of age (inclusive).  
2.  Fitzpatrick Skin Type I – VI (Appendix 3 ). 
3.  Target tattoo contains single or multi -color ink .  
4.  Subject must be able to read, understand and sign the Informed Consent Form.  
5.  Must be willing and able to adhere to the treatment and follow -up schedule and post -
treatment care instructions.  
6.  Wiling to cover tattoos with a bandage or clothing; and/or have very limited sun 
exposure and use an approved sunscreen of SPF 50 or higher on the treated area starting 
2 to 4 weeks before the treatment and/or every day for the duration of the study, 
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 14 of 37                                                       Version 1.0 08 AUG 2016  including the follow -up period.  
7.  Willing to have digital photographs taken of the treatment area and agree to use of 
photographs for presentation, educational or marketing p urposes.  
8.  Agree to not undergo any other procedure(s) for tattoo removal during the study (as 
applicable).  
9.  Post -menopausal or surgically sterilized, or using a medically acceptable form of birth 
control at least 3 months prior to enrollment and during the entire course of the study, 
and no plans to become pregnant for the duration of the study.  
5.1.2 Exclusion Criteria  
Subjects will be excluded from the study if they meet any of the following Exclusion Criteria:  
 
1.  Participation in a clinical trial of a drug or another device  in the target area  during the 
study . 
2.  Target tattoo  contains only black ink . 
3.  History of allergic reaction to pigments following tattooing.  
4.  History of allergy to  local anesthetics . 
5.  History of allergy to topical antibiotics.  
6.  History of malignant tumors in the target area.  
7.  Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.  
8.  Pregnant and/or breastfeeding.  
9.  Having an infection, dermatitis or a rash in the treatment area.  
10.  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., 
uncontrolled hypertension.  
11.  Suffering from coagulation disorders or taking prescription anticoagulation medications.   
12.  History of keloid scarring, hypertrophic scarring or of abnormal wound healing.  
13.  History of immunosuppression/immune deficiency disorders or currently using 
immunosuppressive me dications.  
14.  History of vitiligo, eczema, or psoriasis.  
15.  History of connective tissue disease, such as systemic lupus erythematosus or 
scleroderma.  
16.  History of seizure disorders due to light.  
17.  Any use of medication that is known to increase sensitivity to light according to 
Investigator’s discretion.  
18.  History of disease stimulated by heat, such as recurrent herpes simplex  and/or herpes 
zoster (shingles) in the treatment area, unless treatment is conducted following a 
prophylactic regimen  
19.  History of radiation to the treatment area or undergoing systemic chemotherapy for the 
treatment of cancer.  
20.  History of pigmentary disorders, particularly tendency for hyper - or hypo -pigmentation.  
21.  Systemic use of corticosteroid or isotretinoin within 6 months of study participation.  
22.  Anytime in life, having have used gold therapy (gold salts) for disorders such as 
rheumatologic disease or lupus.  
23.  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning 
during the study.  
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 18 of 37                                                       Version 1.0 08 AUG 2016   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
7 ADVERSE DEVICE EFFECTS  
   
  
 
 
 
 
 
 
 
  
 
 
 
  
   
  
  
  
  
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 19 of 37                                                       Version 1.0 08 AUG 2016    
 
  
 
 
 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
. 
 
  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 20 of 37                                                       Version 1.0 08 AUG 2016   

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 22 of 37                                                       Version 1.0 08 AUG 2016   
 
    
  
  
   
  
    
    
     
  
   
    
  
   
   
   
    
    
    
    
    
   
  
  
   
  
   
    
 
 
    
 
    
 
 
 
    
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 23 of 37                                                       Version 1.0 08 AUG 2016   
 
 
  
8.2 Potential Benefits  
The subjects may or may not benefit from the treatment wi th the study device. Potential benefit of laser 
treatment for  tattoos is  lightening o r complete removal of tattoo. There is no guarantee of success.  
9 RISK MANAGEMENT  
The investigator  participating in this study was chosen based on extensive and safe experience with the 
use of lasers in dermatology applications. This is the most critical element in managing subject risk. In 
addition, study investigators will be trained on the use of the Cutera enlighten  laser  system by a 
representative of Cutera.  
10   DATA ANALYSIS PLAN  
10.1 Sample Size  
Up to 10 subjects will be enrolled in this safety and efficacy study.  
10.2 Demographics and Subject Characteristics at Baseline  
Subject demographics, medical history, concomitant medications will be tabulated and summarized 
descriptively.  
10.3 Statistical Analysis Methods  
10.3.1  Analysis Sets  
The efficacy analysis set will include all subjects who received at least one laser treatment session and 
complete the follow -up visit. The safety analys is set will include all subjects enrolled in the study who 
had at least one laser treatment session.  
 
Missing data will not be imputed for efficacy or safety endpoints.  
10.3.2  Analysis of Primary Endpoint  
Formal statistical analysis is not planned for this study.  The primary efficacy endpoint data, degree of 
tattoo clearing at 6 weeks post -final treatment as assessed by the Investigator (Physician’s Global 
Assessment) , will be summarized descriptively.  
  
  
 
 
  
 
  
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 24 of 37                                                       Version 1.0 08 AUG 2016  10.3.4  Safety Analyses  
Safety variables will be analyzed descriptively.  
 
The safety variables for this study are:  
 
1. Subject discomfort (pain) during and after treatment (to be descriptively displayed).  
2. Incidence and severity of adverse effects during study duration (to be displayed descriptively 
as counts and frequency distributions).  
Device -related and procedure -related adverse effects (AEs) and subjects who prematurely terminate 
from the study due to an adverse device effect, including the treatment -related pain ratings, as reported 
on case report forms will be tabulated and analyzed. For a given AE term, counting will be done by 
subject, not by event, i.e. for a subject reporting the same AE more than once, the event will be counted 
only once, at th e most severe and most -related occurrence.  The number and percentage of subjects 
experiencing each AE Term will be descriptively summarized. Statistical hypothesis testing will not be 
performed for safety data.  
 
  
 
 
 
 
  
12    STUDY MANAGEMENT AND ADMINISTRATIVE PROCEDURES  
   
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 25 of 37                                                       Version 1.0 08 AUG 2016   
 
  
 
 
 
 
 
 
  
 
 
  
 
 
 
 
  
 
 
 
 
  
12.3 Protoc ol Compliance  
The principal investigator must comply with all terms of the protocol.  
12.3.1  Protocol Amendments  
Neither the principal investigator nor the sponsor will modify or alter this protocol without first 
obtaining the concurrence of the other party (with the exception of amendments which involves 
mitigating a medical emergency or immediate health risk to the  subject). The party initiating an 
amendment must confirm it clearly in writing and it must be signed and dated by the sponsor and the 
principal investigator. IRB/ EC approval must be obtained before implementation of an amendment.  
12.3.2   Protocol Deviations  
All protocol deviations must be clearly described on the case report form (i.e., Cutera Protocol Deviation 
Form). Deviations from the protocol may include but are not limited to subject’s failure to attend 
scheduled visit during a visit window, use of out of r ange treatment parameters and incomplete or 
incorrect study procedures. Any medical emergency or immediate health risk to the subject which 
results in a protocol deviation and must be reported to the sponsor within 5 working days  
 
Significant protocol devi ations must be reported to the IRB/ EC according to their policies.  
 
 
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 26 of 37                                                       Version 1.0 08 AUG 2016   
 
12.5 Disclosure of Financial Interest  
Each investigator [principal and sub -investigator(s)] is required t o disclose sufficient accurate financial 
information to the sponsor, to allow sponsor to submit complete and accurate certification or disclosure 
statements.  
 
 
 
  
 
 
 
 
 
 
   
 
 
  
  
  
 
 
  
 
 
  
 
 
 
 
 
 
  
  
 
 
 
  
 
 
  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 27 of 37                                                       Version 1.0 08 AUG 2016   
 
  
 
 
 
 
 
 
  
 
 
 
 
 
  
13    SUBJECT CONFIDENTIALITY  
 
   
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 28 of 37                                                       Version 1.0 08 AUG 2016  14    PUBLICATION POLICY  
The investigator shall have the right to publish the results of the study. Unless mutually agreed upon in 
writing, prior to submission for publication of any manuscript, poster, presentation, abstract or other 
written or oral material describing the results of the study, the investigator shall allow sponsor to review 
manuscript, poster presentation, abstract or other written or oral material which describes the results of 
the study for the purpose only of determ ining if any patentable information is disclosed. At the 
sponsor’s request, the investigator shall withhold any publication or presentation to permit sponsor to 
seek patent protection and to remove any confidential information from all publications.  
 
The International Committee of Medical Journal Editors (ICMJE) member  journals have adopted a trials 
registration policy as a condition for publication. This policy requires that all clinical trials be registered 
in a public trials registry such as ClinicalTri als.gov, which is sponsored by the National Library of 
Medicine. I t is the responsibility of the s ponsor to register this trial in ClinicalTrials.gov. Any clinical trial 
starting enrollment after September 27, 2007 must be registered either on or before th e onset of 
patient enrollment.  
 
 
 
 
 
 
  
Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 29 of 37                                                       Version 1.0 08 AUG 2016    
  
 
  
  
  
  
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
  
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 30 of 37                                                       Version 1.0 08 AUG 2016    
 
  
 
 
 
 
  
 
  
 
  
 
  
 
 
 
  
 
  
 
  
 
  
 
   
 
 
  
 
  
 
  
 
  

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 32 of 37                                                       Version 1.0 08 AUG 2016   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 34 of 37                                                       Version 1.0 08 AUG 2016     
 
  
 
  
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
  
 
 
  
 
 
 
  
 
 
  
 
  
 
  
  
  
  
 
  
 
 
 
 

Cutera, Inc.  
Protocol #  C-16-EN14  
“A Single -Center Pilot Study of a  Novel Multi -Waveleng th Lase r for Tattoo  Removal ” 
 
Confidentia l and Proprietary  Page 37 of 37                                                       Version 1.0 08 AUG 2016   
 
 
 
 
 
 
  
 
 
 
 
 
  
 
  
 
 
  
 
 
 
  
 
  
 
  
 
  
 
  
  
  
  
  
  
 
 
 
